X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
TEVA PHARMA
Dec-13
TORRENT PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7682,840-   
Low Rs1,1862,467-   
Sales per share (Unadj.) Rs346.11,629.9-  
Earnings per share (Unadj.) Rs55.2101.8-  
Cash flow per share (Unadj.) Rs73.3233.6-  
Dividends per share (Unadj.) Rs14.0089.13-  
Dividend yield (eoy) %0.93.4 28.2%  
Book value per share (Unadj.) Rs257.11,810.5-  
Shares outstanding (eoy) m169.22848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.6 262.1%   
Avg P/E ratio x26.826.1 102.7%  
P/CF ratio (eoy) x20.111.4 177.3%  
Price / Book Value ratio x5.71.5 391.9%  
Dividend payout %25.487.5 29.0%   
Avg Mkt Cap Rs m249,8872,250,219 11.1%   
No. of employees `00011.844.9 26.2%   
Total wages/salary Rs m9,9340-   
Avg. sales/employee Rs Th4,971.530,752.4 16.2%   
Avg. wages/employee Rs Th843.20-   
Avg. net profit/employee Rs Th792.41,921.1 41.3%   
INCOME DATA
Net Sales Rs m58,5691,382,165 4.2%  
Other income Rs m2,2330-   
Total revenues Rs m60,8021,382,165 4.4%   
Gross profit Rs m13,773378,507 3.6%  
Depreciation Rs m3,069111,722 2.7%   
Interest Rs m2,05627,148 7.6%   
Profit before tax Rs m10,881239,637 4.5%   
Minority Interest Rs m01,089 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-157,308 0.0%   
Tax Rs m1,545-2,926 -52.8%   
Profit after tax Rs m9,33686,343 10.8%  
Gross profit margin %23.527.4 85.9%  
Effective tax rate %14.2-1.2 -1,163.1%   
Net profit margin %15.96.2 255.2%  
BALANCE SHEET DATA
Current assets Rs m53,841933,509 5.8%   
Current liabilities Rs m31,612814,099 3.9%   
Net working cap to sales %38.08.6 439.3%  
Current ratio x1.71.1 148.5%  
Inventory Days Days9791 107.0%  
Debtors Days Days8496 87.3%  
Net fixed assets Rs m42,079451,445 9.3%   
Share capital Rs m8463,402 24.9%   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,5011,535,323 2.8%   
Long term debt Rs m22,408706,731 3.2%   
Total assets Rs m101,2503,158,689 3.2%  
Interest coverage x6.39.8 64.0%   
Debt to equity ratio x0.50.5 111.9%  
Sales to assets ratio x0.60.4 132.2%   
Return on assets %11.33.6 313.1%  
Return on equity %21.55.6 381.6%  
Return on capital %19.64.9 398.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,127220,245 4.6%  
From Investments Rs m-7,869-78,042 10.1%  
From Financial Activity Rs m-1,918-264,199 0.7%  
Net Cashflow Rs m212-121,996 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare TORRENT PHARMA With: ORCHID PHARMA LTD  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views On News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 18, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SUVEN LIFE COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS